BARD1 has an experienced board and management team with a track record in building successful companies, and international expertise in BARD1 biology, biomarker translation and respiratory medicine.
Dr Leearne Hinch Chief Executive Officer
Dr Leearne Hinch BSc, BVMS, MBA is a highly qualified senior executive with extensive experience in biotechnology and life sciences. Leearne has built a strong track record in general management, strategy, fundraising, business development and commercialisation. She has held senior executive, management and consulting positions in ASX-listed biotechnology, multinational and private companies where she led the development and commercialisation of multiple diagnostic, device, therapeutic and animal health products. Leearne holds Bachelor of Science, Bachelor of Veterinary Medicine and Surgery, and a Master of Business Administration.
Carl Stubbings Chief Operations Officer
Carl Stubbings, B App Sc (Med Tech) has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics, one of the world’s largest pathology laboratories. In July 2012, Carl moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC). More recently he has been assisting several Australian biotech companies with their commercialisation strategies. These companies include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercialising anti-viral small molecule therapies. He was previously a Non-executive Director of ASX listed medical device company Analytica Medical Limited (ASX: ALT) and Managing Director of Sienna Cancer Diagnostics Ltd (ASX:SDX).
Tony Di Pietro Chief Financial Officer & Company Secretary
Tony Di Pietro B. Comm, CA, AGIA, MAICD is a Chartered Accountant with significant corporate accounting experience, gained both in Australia and the UK. He holds a Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia and is a member of the Australian Institute of Company Directors. Tony has held senior roles within the Biotechnology/MedTech industry for the past 15 years including Sienna Cancer Diagnostics Ltd (ASX; SDX) and gained valuable experience in other industry sectors, employed by companies such as BHP Ltd, ExxonMobil Ltd, HSBC Ltd and Wilson Group.
Peter French Chief Scientific Officer
Dr French BSc, MSc, PhD, MBA is a leading biotechnology executive and respected scientist with extensive CSO, CEO and director experience. He has a strong track record in commercialising medical innovations with over 40 years’ scientific expertise in cell and molecular biology and over 40 peer reviewed publications across oncology, immunology, microbiology and neuroscience. His previous industry roles included provided strategic and scientific consulting services, executive director of AusDiagnostics Pty Ltd, Bioxyne Ltd and BCAL Diagnostics, Managing Director of Benitec Biopharma Ltd, and founder and non-executive director of Cryosite Ltd (ASX:CTE). Dr French also had a successful academic career as Principal Scientist at the Centre for Immunology, St Vincent’s Hospital and Post-Doctoral Research Scientist at the Children’s Medical Research Foundation. He was awarded the Faculty of Science Alumni Achievement Award for Innovation and Entrepreneurship in 2019 from the University of Sydney.